NCT02601573View on ClinicalTrials.gov

Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)

PHASE2CompletedINTERVENTIONAL

Enrollment

101

Participants

Timeline

Start Date

January 5, 2016

Primary Completion Date

October 18, 2016

Study Completion Date

January 6, 2017

Conditions

Hepatitis C

Interventions

DRUG

Grazoprevir

GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.

DRUG

Elbasvir

EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

DRUG

Ribavirin

RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).

DRUG

Sofosbuvir

SOF 400 mg tablet taken q.d. by mouth in the morning with food.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02601573 - Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083) | Biotech Hunter | Biotech Hunter